Want to join the conversation?
Pharma company $MYL announced the US launch of Dextroamphetamine Sulfate extended-release capsules for treatment of narcolepsy and attention deficit disorder with hyperactivity. $MYL received final approval from the US FDA for its ANDA for this product, which had US sales of approx. $101.3MM for the 12 months ending May 31, 2016.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.